FY2025 Earnings Estimate for PTCT Issued By Leerink Partnrs

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for PTC Therapeutics in a research report issued to clients and investors on Tuesday, November 4th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of $5.52 per share for the year, down from their previous forecast of $8.33. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics’ Q4 2025 earnings at ($0.97) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.66) EPS and FY2027 earnings at ($0.89) EPS.

Several other research firms have also issued reports on PTCT. Robert W. Baird set a $70.00 price target on shares of PTC Therapeutics in a report on Friday, August 8th. TD Cowen raised their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday. The Goldman Sachs Group boosted their target price on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research note on Wednesday. Bank of America reduced their target price on PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Finally, Truist Financial raised their price target on PTC Therapeutics from $80.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $75.40.

PTC Therapeutics Stock Down 1.1%

NASDAQ PTCT opened at $71.78 on Friday. PTC Therapeutics has a 52 week low of $35.95 and a 52 week high of $73.98. The company has a 50 day moving average price of $63.31 and a 200 day moving average price of $53.60. The firm has a market cap of $5.70 billion, a PE ratio of 10.30 and a beta of 0.60.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. During the same period in the prior year, the firm posted ($1.39) earnings per share. The company’s quarterly revenue was up 7.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS.

Insiders Place Their Bets

In related news, Director Allan Steven Jacobson sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $65.00, for a total value of $780,000.00. Following the sale, the director owned 17,451 shares in the company, valued at $1,134,315. This represents a 40.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Mark Elliott Boulding sold 24,585 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $61.34, for a total transaction of $1,508,043.90. Following the completion of the transaction, the vice president owned 103,901 shares in the company, valued at approximately $6,373,287.34. This trade represents a 19.13% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 254,662 shares of company stock valued at $16,000,821. Insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

Several large investors have recently made changes to their positions in PTCT. Nuveen LLC acquired a new stake in shares of PTC Therapeutics in the first quarter worth $51,427,000. Wellington Management Group LLP lifted its position in PTC Therapeutics by 13.2% during the first quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company’s stock valued at $276,161,000 after purchasing an additional 632,049 shares during the period. Hood River Capital Management LLC boosted its holdings in PTC Therapeutics by 654.4% in the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock valued at $31,087,000 after purchasing an additional 552,130 shares during the last quarter. State Street Corp grew its position in PTC Therapeutics by 22.1% during the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock worth $146,347,000 after purchasing an additional 541,558 shares during the period. Finally, Driehaus Capital Management LLC grew its position in PTC Therapeutics by 45.3% during the 1st quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company’s stock worth $77,084,000 after purchasing an additional 471,586 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.